0

Category: EMPA REG

GLP-1 Receptor Agonists and SGLT-2 Inhibitors: A Dynamic Duo?

September 23, 2016

First clinical trial to study GLP-1 receptor agonist and SGLT-2 inhibitor combination shows positive results

Experts have speculated that combination GLP-1 receptor agonist and SGLT-2 inhibitor therapy may have synergistic, beneficial effects in the treatment of type 2 diabetes. Now there are data to support this, as results of DURATION-8, the first clinical trial to study the combination as an addition to standard-of-care therapy, were recently announced at the European Association for the Study of Diabetes (EASD) 2016 Annual Meeting and published in the Lancet Diabetes and Endocrinology. Read more

Share onShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

Are We Any Closer to Understanding What’s Driving the Cardiovascular Benefits Seen in EMPA-REG?

Theories abound on what’s driving the cardiovascular benefits seen in EMPA-REG, as an FDA advisory panel votes to support a claim of CV risk reduction on the SGLT-2 inhibitor empagliflozin’s label.

An advisory panel to the US FDA has voted, albeit narrowly, to allow the claim that treatment with the SGLT-2 inhibitor epagliflozin reduces the risk of cardiovascular death in patients with type 2 diabetes. Results of EMPA-REG, which were published last year, showed that the drug reduced cardiovascular death by 38% and reduced the combined risk of cardiac death, non-fatal myocardial infarction, and non-fatal stroke by 14%. The potential mechanisms by which empagliflozin works to reduce this cardiovascular risk are still not known, however, and were the focus of discussion at the recent ADA 2016 Scientific Sessions.

Read more

Share onShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn